Goldman Sachs Group Inc. lifted its stake in Insys Therapeutics, Inc. (NASDAQ:INSY) by 2.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 137,453 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,785 shares during the period. Goldman Sachs Group Inc. owned 0.19% of Insys Therapeutics worth $1,738,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Point72 Asset Management L.P. increased its holdings in shares of Insys Therapeutics by 24.8% in the first quarter. Point72 Asset Management L.P. now owns 435,000 shares of the specialty pharmaceutical company’s stock valued at $4,572,000 after purchasing an additional 86,373 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Insys Therapeutics by 3.2% in the second quarter. Northern Trust Corp now owns 314,825 shares of the specialty pharmaceutical company’s stock valued at $3,983,000 after purchasing an additional 9,906 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Insys Therapeutics by 9.7% in the first quarter. Geode Capital Management LLC now owns 305,044 shares of the specialty pharmaceutical company’s stock valued at $3,206,000 after purchasing an additional 26,913 shares in the last quarter. FMR LLC increased its holdings in shares of Insys Therapeutics by 4.7% in the second quarter. FMR LLC now owns 254,588 shares of the specialty pharmaceutical company’s stock valued at $3,221,000 after purchasing an additional 11,504 shares in the last quarter. Finally, Strs Ohio increased its holdings in shares of Insys Therapeutics by 40.0% in the second quarter. Strs Ohio now owns 175,000 shares of the specialty pharmaceutical company’s stock valued at $2,213,000 after purchasing an additional 50,000 shares in the last quarter. 25.48% of the stock is owned by institutional investors and hedge funds.

In other Insys Therapeutics news, major shareholder John N. Kapoor Trust Dated Sept purchased 17,500 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was purchased at an average cost of $8.93 per share, for a total transaction of $156,275.00. Following the transaction, the insider now owns 31,982 shares in the company, valued at approximately $285,599.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Saeed Motahari purchased 5,500 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average price of $8.92 per share, with a total value of $49,060.00. Following the completion of the transaction, the chief executive officer now owns 15,400 shares in the company, valued at approximately $137,368. The disclosure for this purchase can be found here. Corporate insiders own 67.90% of the company’s stock.

A number of analysts recently weighed in on the stock. BidaskClub raised shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 8th. Zacks Investment Research cut shares of Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada reduced their price objective on shares of Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, August 4th. Finally, Piper Jaffray Companies set a $10.00 price objective on shares of Insys Therapeutics and gave the company a “hold” rating in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Insys Therapeutics has a consensus rating of “Hold” and an average target price of $10.13.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The firm had revenue of $42.60 million during the quarter, compared to analysts’ expectations of $36.90 million. During the same period in the prior year, the company posted $0.13 EPS. The company’s revenue was down 38.4% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: “Goldman Sachs Group Inc. Raises Position in Insys Therapeutics, Inc. (INSY)” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://theolympiareport.com/2017/11/02/goldman-sachs-group-inc-raises-position-in-insys-therapeutics-inc-insy.html.

Insys Therapeutics Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.